

News Releases

All Years

Search

Go

[Advanced Search](#)

FEB 1, 2021

Inhibrx Announces Participation in Upcoming Investor Conference

JAN 13, 2021

Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients

JAN 5, 2021

Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist

NOV 13, 2020

Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford

NOV 11, 2020

Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

Show per page

« 1 ... 8 9 10 11 12 13 14 15 16 »



